REG - GENinCode PLC - Notice of AGM and posting of Annual Report

GenincodeAnnouncement

08/06/2023 13:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230608:nRSH1468Ca&default-theme=true

RNS Number : 1468C  GENinCode PLC  08 June 2023

GENinCode Plc

("GENinCode" or the "Company")

 

Posting of Annual Report to Shareholders and Notice of Annual General Meeting

 

Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused
on the prevention of cardiovascular disease, confirms that the Annual Report
and Accounts for the year ended 31 December 2022 and the Notice of Annual
General Meeting ("AGM") have been posted to shareholders.

 

A copy of the 2022 Annual Report and Accounts, the Notice of AGM and
accompanying form of proxy is now available to download from the Company
website in accordance with AIM Rule 20:

 

https://investors.genincode.com/investors
(https://investors.genincode.com/investors)

 

The AGM will be held in person at the offices of Cenkos Securities plc, 6,7,8
Tokenhouse Yard, London EC2R 7AS on Friday, 30 June 2023 at 2.00 p.m.

 

For more information visit www.genincode.com (http://www.genincode.com)

 

Enquiries:

 

 GENinCode Plc                          www.genincode.com (http://www.genincode.com) or via Walbrook PR
 Matthew Walls, CEO
 Paul Foulger, CFO

 Stifel Nicolaus Europe Limited (Nomad and Joint Broker)                                      Tel: +44 (0)20 7710 7600
 Alex Price / Ben Maddison / Richard Short

 Cenkos Securities Plc (Joint Broker)   Tel: +44 (0)20 7397 8900
 Giles Balleny
 Dale Bellis / Michael Johnson (Sales)

 Walbrook PR Limited                                                Tel: 020 7933 8780 or genincode@walbrookpr.com

                                                                  (mailto:genincode@walbrookpr.com)
 Anna Dunphy / Louis Ashe-Jepson / Phillip Marriage

 

About GENinCode:

GENinCode Plc is a UK based company specialising in genetic risk assessment of
cardiovascular disease. Cardiovascular disease is the leading cause of death
and disability worldwide.

 

GENinCode operates business units in the UK, Europe through GENinCode S.L.U,
and in the United States through GENinCode U.S. Inc.

 

GENinCode predictive technology provides patients and physicians with globally
leading preventative care and treatment strategies. GENinCode CE marked
invitro-diagnostic molecular tests combine clinical algorithms and
bioinformatics to provide advanced patient risk assessment to predict the
onset of cardiovascular disease.

 

About Cardiovascular Disease (CVD):

 

CVD is the leading cause of death globally, taking an estimated 17.9 million
lives each year. CVD is a group of disorders of the heart and blood vessels
and include coronary heart disease, cerebrovascular disease, rheumatic heart
disease and other conditions. More than four out of five CVD deaths are due to
heart attacks and strokes, and one third of these deaths occur prematurely in
people under 70 years of age.

 

CVD causes a quarter of all deaths in the UK and is the largest cause of
premature mortality in deprived areas with the NHS 10 Year Plan identifying
CVD as the single biggest area where the NHS can save lives over the next 10
years. CVD is largely preventable, through lifestyle changes and a combination
of public health and NHS action on smoking and tobacco addiction, obesity,
tackling alcohol misuse and food reformulation.

 

Early detection and treatment of CVD can help patients live longer, healthier
lives. Too many people are still living with undetected, high-risk conditions
such as high blood pressure, raised cholesterol, and atrial fibrillation (AF).
The NHS 10 Year Plan is working towards people knowing and managing risks
around their 'ABC' (AF, Blood pressure and Cholesterol).

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOALVLFBXQLLBBV